Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

BACKGROUND: Venous thromboembolic events (VTEs) are common and potentially fatal complications in cancer patients, and they are responsible for the second most common cause of death. Low molecular weight heparin (LMWH) is the gold-standard treatment, but the costs involved limit its use, especially...

Descripción completa

Detalles Bibliográficos
Autores principales: Xavier, Flávia Dias, Hoff, Paulo Marcelo Gehm, Braghiroli, Maria Ignez, Paterlini, Ana Carolina Carvalho Rocha, Souza, Karla Teixeira, Faria, Luiza Dib Batista Bugiato, Ferreira, Fernando Sergio Blumm, Machado, Karime Kalil, Fernandes, Gustavo dos Santos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2016
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493228/
https://www.ncbi.nlm.nih.gov/pubmed/28717737
http://dx.doi.org/10.1200/JGO.2015.002527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493228/
https://www.ncbi.nlm.nih.gov/pubmed/28717737
http://dx.doi.org/10.1200/JGO.2015.002527

Ejemplares similares